Beijing Okeanos Technology

Founded in 2006, Beijing Okeanos Technology Co., Ltd. is a high-tech enterprise focused on the life sciences sector. The firm develops and produces special chemical and biological reagents, as well as pharmaceutical intermediates. Its primary offerings include modified and unnatural amino acids, nucleoside derivatives, heterocyclic compounds, and fluorescent labeling reagents, which are crucial for sequencing and synthetic biology.

The company operates on a business-to-business model, providing custom synthesis and manufacturing services. Its client base includes major international pharmaceutical and chemical companies such as Pfizer, Novartis, P&G, and Dow. Revenue is generated through the sale of its chemical compounds and intermediates, as well as custom synthesis projects. The technical team is composed of talent from Peking University, Tsinghua University, and the Chinese Academy of Sciences, supported by an expert advisory board. This has enabled the company to secure over 80 patents.

Beijing Okeanos Technology has established a significant research and development footprint, with over 1,000 square meters of laboratory space. The company has also engaged in long-term scientific collaborations with renowned institutions, including Harvard University and Stanford University, to remain at the forefront of biochemical research. The company has successfully completed several funding rounds, including a Series B+ in December 2022. Its investors include Qiming Venture Partners, Gopher Asset Management, and CMB International Capital.

Keywords: biochemical reagents, life sciences, pharmaceutical intermediates, custom synthesis, modified nucleotides, unnatural amino acids, fluorescent labeling, nucleoside derivatives, synthetic biology, chemical manufacturing, R&D, biotechnology, specialty chemicals, sequencing reagents, heterocyclic compounds, pharmaceutical chemistry, organic chemistry, drug discovery